Qiagen Forecast, price target & analysts
Qiagen Target price 2026 - Analyst rating & recommendation
Qiagen Classifications & Recommendation
Qiagen Price Target
| Target Price | €43.87 |
| Price | €45.10 |
| Deviation | 2.73% |
| Number of Estimates | 17 |
| 17 Analysts have issued a price target Qiagen 2027 . The average Qiagen target price is €43.87. This is 2.73% lower than the current stock price. The highest price target is €51.74 14.73% , the lowest is €36.20 19.74% . | |
| A rating was issued by 23 analysts: 11 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2027 of 2.73% . Most analysts recommend the Qiagen stock at Hold. |
Sales and Margin forecast 2026, 2027 to 2030
24 Analysts have issued a sales forecast Qiagen 2026 . The average Qiagen sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
22 Analysts have issued an Qiagen EBITDA forecast 2026. The average Qiagen EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
24 Qiagen Analysts have issued a net profit forecast 2026. The average Qiagen net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031
Current Qiagen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Neutral
|
Downgrade | Oct 22 2026 |
| Baird |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 14 2026 |
| Barclays |
Equal-Weight
➜
Overweight
|
Upgrade | Oct 06 2026 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Sep 09 2026 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 10 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Downgrade
JP Morgan:
Overweight
➜
Neutral
|
Oct 22 2026 |
|
Unchanged
Baird:
Outperform
➜
Outperform
|
Oct 22 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 14 2026 |
|
Upgrade
Barclays:
Equal-Weight
➜
Overweight
|
Oct 06 2026 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Sep 09 2026 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 10 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 07 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
